GlassScriptPhysician profile
James E Livesay
NPI 1063945673
$10,305.09
in general payments reported to CMS, 2019-2025
24 companies · $7,270 in 2025
The $7,270 reported for 2025 was more than what 87% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $175 · 2023: $823 · 2024: $2,037 · 2025: $7,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,541 · Travel and Lodging: $2,989 · Consulting Fee: $530 · Education: $70.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,540.56 |
| Travel and Lodging | $2,988.80 |
| Consulting Fee | $530.00 |
| Education | $70.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $6,323.92 | 2024-2025 | Sapien 3 Ultra Resilia, Evoque, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $1,368.05 | 2023-2025 | Impella |
| Boston Scientific Corporation | $857.25 | 2023-2025 | Avvigo Guidance System, Watchman Flx, Fighter |
| Medtronic, INC. | $329.51 | 2025 | Corevalve Evolut R, Onyx Frontier |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $310.61 | 2024-2025 | Lifevest |
| Abbott Laboratories | $179.52 | 2024-2025 | Triclip, Ensite, Viewmate |
| E.R. Squibb & Sons, L.L.C. | $174.77 | 2022 | |
| Cardiac Dimensions, INC. | $109.79 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $85.99 | 2023 | Arcalyst |
| Biosense Webster, INC. | $76.73 | 2024-2025 | Carto 3 |
| Actelion Pharmaceuticals US, INC. | $72.43 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Shockwave Medical, INC | $69.96 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $62.11 | 2025 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $47.08 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $35.23 | 2025 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.33 | 2023 | Jardiance |
| Philips North America LLC | $31.38 | 2024 | (6342) Intrasight Integrated |
| Pfizer INC. | $28.86 | 2024 | |
| Heartflow, INC. | $26.16 | 2024 | |
| Alnylam Pharmaceuticals INC. | $19.20 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $19.00 | 2025 | |
| Genzyme Corporation | $16.69 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.01 | 2024 | Xarelto |
| Altathera Pharmaceuticals LLC | $12.51 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Livesay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.